[Skip to Navigation]
Nov 2011

Superselective Intraophthalmic Artery Chemotherapy: What We Do Not Know

Author Affiliations

Author Affiliations: Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Center (Drs Wilson, Haik, and Dyer), and Departments of Surgery (Drs Wilson and Haik), Pathology (Dr Wilson), and Developmental Neurobiology (Dr Dyer), Division of Ophthalmology (Drs Wilson and Haik), St Jude Children's Research Hospital, Memphis, Tennessee.

Arch Ophthalmol. 2011;129(11):1490-1491. doi:10.1001/archophthalmol.2011.361

In 2008, Abramson and colleagues1 brought to our attention the unprecedented response of intraocular retinoblastoma to superselective intraophthalmic artery chemotherapy (SSIOAC), which rapidly became a primary treatment for both unilateral and bilateral intraocular retinoblastoma2,3 adopted by retinoblastoma centers worldwide. The enthusiasm for SSIOAC results from the reported dramatic responses and mitigated toxicities associated with primary systemic chemotherapy. Nonetheless, reservations regarding the technique have been voiced,4-7 and although others have pushed ahead, we are hesitant to adopt SSIOAC for our patients.

Add or change institution